Zoetis to Present Data, Tools and Education on the Management of Osteoarthritis (OA) Pain at the 2019 World Small Animal Veterinary Association (WSAVA) Conference

Data on the Role of Anti-NGF (Nerve Growth Factor) in the Management of OA Pain Pathway to Be Highlighted 

PARSIPPANY, N.J., July 10, 2019Zoetis today announced it will present data and share innovative tools and insights into osteoarthritis (OA) pain control at the 2019 World Small Animal Veterinary Association (WSAVA) Conference in Toronto, Canada, from July 16-19, 2019. The company will highlight a new approach that targets NGF (Nerve Growth Factor) in the pain pathway to enable long-lasting OA pain relief. Several presentations related to research and development in chronic OA pain are scheduled as part of Zoetis’ continued commitment to veterinarians.

“Anti-NGF therapy will undoubtedly play a large role in OA pain management, and it’s important for us to share insights with the veterinary community especially when dogs and cats cannot speak for themselves,” said Joyce Login, DVM, Veterinary Medical Lead, Pain, Oncology and Specialty at Zoetis. “Our data builds on more than 30 years of research and commitment to companion animal pain management. We look forward to presenting at the 2019 WSAVA conference and afterwards making materials available through our new interactive website.”

Highlights of OA-related activities planned by Zoetis at the Conference include: 

  • New Interactive Website for Veterinarians: Zoetis plans to unveil a website, “The New Science of Osteoarthritis Pain” (www.TheNewScienceofOAPain.com), for veterinarians. The website will offer veterinarians the opportunity to discover new science and new tools to support diagnosing and treating osteoarthritis in cats and dogs. It will feature videos highlighting the keys to a successful OA exam for cats. It is estimated that 40% of all cats have clinical signs of OA1 and the prevalence of OA in dogs is believed to be greater than 23%.
  • Pre-Conference Educational Event: Zoetis will host an educational event entitled, “The (UN)usual Suspects with Osteoarthritis Pain: Who Are We Missing and How Do We Find Them?”, which focuses on the latest tools and techniques to help identify OA pain in cats and dogs. It will feature a speaker panel discussing the current diagnostics along with new therapies on the horizon. The event will take place on Monday, July 15 from 8:00 am - 5:35 pm EDT at the Metro Toronto Convention Center, Hall Room 701. Please visit the following link to learn more: https://wsava2019.com/pre-congress-sessions/#1541491481549-011c7d71-7bc8
  • Data Related to Chronic OA and NGF to be Presented:

    • Nerve growth factor, pain and monoclonal antibodies (mAbs) for chronic pain 
    (Dr. Duncan Lascelles; July 17, 8:00 am - 8:50 am EDT, Hall Room 701)

    • Identifying and measuring osteoarthritis pain in young dogs 
    (Dr. Duncan Lascelles; July 17, 8:55 am - 9:45 am EDT, Hall Room 701

    • Identifying osteoarthritis pain in cats
    (Dr. Margaret E. Gruen; July 17, 10:45 am - 11:35 am EDT, Hall Room 701)

    • Quality of life assessment in cats with chronic osteoarthritis pain 
    (Dr. Margaret E. Gruen, July 17, 1:45 pm - 2:10 pm EDT, Hall Room 701)

“We look forward to discussing the central role of NGF as a driver of osteoarthritis pain at this year’s conference,” said Dr. Duncan Lascelles, BSc, BVSc, PhD, MRCVS, CertVA, DSAS(ST), DECVS, DACVS Professor of Small Animal Surgery and Pain Management, North Carolina State University, Raleigh, NC. “With new approaches and a novel pain pathway on the horizon, we have an opportunity to significantly advance the way we manage OA pain for feline and canines.” 

About Zoetis 
Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and commercializes medicines, vaccines and diagnostic products, which are complemented by biodevices, genetic tests and a range of services. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2018, the company generated annual revenue of $5.8 billion with approximately 10,000 employees. For more information, visit www.zoetis.com

For further information contact:
Colleen White

Chris Vancheri

1 Slingerland L, Hazewinkel H, Meij B, Picavet P, Voorhout G: Cross-sectional study of the prevalence and clinical features of osteoarthritis in 100 cats. Vet J 2011: 187: 304-9.
2 Johnston SA. Vet Clin North Amer; 1997;27(4)699-723.



Mon–Fri, 8:30am–8:00pm ET

This site is intended for U.S. Animal Healthcare Professionals. The product information provided in this site is intended only for residents of the United States. The products discussed herein may not have marketing authorization or may have different product labeling in different countries. The animal health information contained herein is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. All decisions regarding the care of a veterinary patient must be made with an animal healthcare professional, considering the unique characteristics of the patient.

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted. ©2022 Zoetis Services LLC. All rights reserved.